TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

Inclusion Criteria: * Patients aged 18-75 years with hepatocellular carcinoma have an expected survival of at least 3 months; * Number of tumors ≤ 3; * Large hepatocellular carcinoma with tumor diameter ≥ 7 cm; * Patients without inferior vena cava tumor thrombus, portal vein tumor thrombus and cholangiocarcinoma thrombus; * Although there is arteriovenous fistula or arterioportal fistula, it can be completely blocked; * Child Pugh grade A or B of liver function; ECoG physical fitness score \< 2; * No bleeding tendency, normal coagulation function or coagulation dysfunction can be corrected after treatment; * Leukocyte count ≥ 3.0 × 109/L； * Hemoglobin ≥ 8.5g/dl; * Platelet count ≥ 50 × 109/L； * The international normalized ratio of prothrombin time (INR) ≤ 2.3 or prothrombin time (PT) does not exceed the upper limit of normal control for 3 seconds; * Serum creatinine was less than 1.5 times of the upper limit of normal; * Patients and / or family members agree to join the clinical trial and sign the informed consent form Exclusion Criteria: * Diffuse hepatocellular carcinoma; * Portal vein tumor thrombus; * Combined with tumor thrombus of hepatic vein and inferior vena cava; * Patients with lymph node metastasis and extrahepatic distant metastasis; * The liver function was classified as child Pugh C and could not be improved by liver protection treatment; * Arteriovenous fistula or arterioportal fistula with ineffective intervention; * Uncorrectable coagulation dysfunction and obvious hemogram abnormalities, with obvious bleeding tendency; * Intractable massive ascites; * ECoG physical fitness score \> 2 points; * Combined with active infection, especially bile duct inflammation; * Serious heart, lung, kidney, brain and other important organ diseases; * Note: see attached table 1 for child Pugh classification of liver function; See attached table 2 for ECoG physical fitness score